OCA-B Peptide Conjugates for Type 1 Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 1 Diabetes (T1D) and multiple sclerosis (MS) are limited by incomplete understanding of disease pathogenesis, leading to ineffective therapies that often disrupt normal immune function, and there is a need for methods to block autoimmune responses while preserving immune function.
Innovation Solution
Development of membrane-permeable peptides that inhibit the interaction between OCA-B and Jmjd1a, using a peptide comprising OCA-B or its fragment, a linker, and a cell-penetrating peptide to block the interaction, thereby reducing pathogenic T cell function in T1D and modulating immune responses in MS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional immune-disrupting therapies are used to treat autoimmune diseases, then autoimmune responses are suppressed, but normal immune function is disrupted
Solution Approach 1:
The peptide inhibitor is designed to act locally at the OCA-B/Jmjd1a interaction site within the nucleus of T cells, specifically blocking the transcriptional co-activation complex without affecting other immune pathways. This localized action suppresses autoimmune responses while preserving overall immune function.
Solution Approach 2:
The peptide inhibitor serves as an intermediary molecule that binds to the OCA-B/Jmjd1a complex and blocks their interaction. This mediator approach allows selective interruption of the pathological transcriptional activation without directly suppressing the entire immune system, thereby maintaining immune reliability.
2Object-generated harmful factors
If OCA-B activity is inhibited to reduce pathogenic T cell function, then autoimmune damage is reduced, but T cell-mediated immunity may be compromised
Solution Approach 1:
The peptide inhibitor partially blocks OCA-B activity by interfering with its interaction with Jmjd1a, rather than completely inhibiting OCA-B function. This partial action is sufficient to reduce pathogenic T cell responses while allowing enough residual OCA-B activity to maintain protective T cell immunity.
3Object-affected harmful factors
If broad immune suppression is applied to treat autoimmune diseases, then disease symptoms are reduced, but global immune deregulation occurs
Solution Approach 1:
The therapeutic approach segments the immune system's regulatory pathways by specifically targeting the OCA-B/Jmjd1a transcriptional complex in T cells. This segmentation allows selective suppression of autoimmune pathology through a defined molecular mechanism while leaving other immune regulatory pathways intact, preserving immune adaptability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively reduce T cell infiltration and pro-inflammatory cytokine production in the pancreas, alleviating T1D symptoms and protecting against autoimmune responses without global immune deregulation, suggesting a therapeutic avenue for these diseases.
Implementation Method 1
a cell penetrating peptide
Data Source
AI summary
Disclosed herein, are compounds comprising a peptide, wherein the peptide is OCA-B or an OCA-B fragment thereof; a linker; and a cell penetrating peptide. Also described herein, are methods of administering compounds to subjects for the treatment of Type I diabetes and blocking the interaction between OCA-B and Jmjd1a.